Highlights Talphera, Inc.

Equities

TLPH

US00444T2096

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
1.015 ^USD	-0.49%		-0.49%	+38.10%

06/03	Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
06/03	Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	18/01	CI
Talphera Expects to Initiate the Registrational Study of Niyad	09/01	CI
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	09/11	CI
AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study	03/23/03	CI
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Vertical Pharmaceuticals, LLC acquired DSUVIA from AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) for $119.2 million.	03/23/03	CI
AcelRx Pharmaceuticals Q4 Loss Narrows After Sales Jump	31/23/31	MT
Earnings Flash (ACRX) ACELRX PHARMACEUTICALS Reports Q4 Revenue $252,000	31/23/31	MT
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	31/23/31	CI
Vertical Pharmaceuticals, LLC agreed to acquire DSUVIA from AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) for $120 million.	14/23/14	CI
AcelRx Pharmaceuticals, Inc. Announces Peer-Reviewed Publication on the Use of Dsuvia(R) for in Office Rhinology Procedures	01/23/01	CI
AcelRx Pharmaceuticals, Inc. Announces Termination of Manufacturing Services Agreement with Patheon Pharmaceuticals Inc	06/22/06	CI
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Earnings Flash (ACRX) ACELRX PHARMACEUTICALS Reports Q3 Revenue $507,000, vs. Street Est of $0.625M	15/22/15	MT
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022	31/22/31	CI
AcelRx Pharmaceuticals, Inc. Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022	26/22/26	CI
AcelRx Pharmaceuticals Initiates 1-for-20 Reverse Stock Split	26/22/26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Talphera, Inc.

Equities

TLPH

US00444T2096

Highlights

Filters